Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

QNCX

Quince Therapeutics Inc

Apr 14 • 04:00PM ET

1.25

-0.16 -11.35 %

Healthcare • Biotechnology • USA • NASD

Peers: IMCR BEAM NTLA CRSP EDIT VERV PRME RNA MGTX RPRX

| Held by: VTI VXF IWC

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-16.43	Insider Own	13.18%	Shs Outstand	5.57M	Perf Week	-23.31%
Market Cap	20.38M	Forward P/E	-	EPS next Y	-0.54	Insider Trans	-6.38%	Shs Float	4.83M	Perf Month	17.37%
Enterprise Value	21.10M	PEG	-	EPS next Q	-1.56	Inst Own	-	Short Float	28.63%	Perf Quarter	-95.76%
Income	-83.98M	P/S	-	EPS this Y	38.99%	Inst Trans	45.24%	Short Ratio	0.13	Perf Half Y	-93.32%
Sales	0.00M	P/B	-	EPS next Y	92.11%	ROA	-76.42%	Short Interest	1.38M	Perf YTD	-96.27%
Book/sh	-6.41	P/C	1.15	EPS next 5Y	-	ROE	-247.78%	52W High	45.50 -97.25%	Perf Year	-87.75%
Cash/sh	1.09	P/FCF	-	EPS past 3/5Y	-2.82% 8.64%	ROIC	-	52W Low	0.80 56.25%	Perf 3Y	-91.88%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	47.70% 26.36%	Perf 5Y	-99.66%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-25.06%	Oper. Margin	-	ATR (14)	0.52	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	0.53	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	40.96	Recom	3.40
Dividend Gr. 3/5Y	- -	Current Ratio	0.53	EPS Q/Q	-149.43%	SMA20	13.34%	Beta	1.40	Target Price	55.00
Payout	-	Debt/Eq	-	Sales Q/Q	-	SMA50	-12.73%	Rel Volume	0.28	Prev Close	1.41
Employees	38	LT Debt/Eq	-	Earnings	Mar 03	SMA200	-92.50%	Avg Volume	10.41M	Price	1.25
IPO	May 09, 2019	Option/Short	Yes / Yes	EPS/Sales Surpr.	4.21% -	Trades		Volume	3,030,740	Change	-11.35%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-30-26	Downgrade	Citizens JMP	Mkt Outperform → Mkt Perform
Aug-05-25	Initiated	Citizens JMP	Mkt Outperform	$9
Mar-24-25	Initiated	Oppenheimer	Outperform	$10

Apr-10-26 10:30AM	BC-Most Active Stocks (Associated Press) +10.19%
Apr-09-26 10:30AM	BC-Most Active Stocks (Associated Press) -32.44%
Apr-08-26 10:30AM	BC-Most Active Stocks (Associated Press) +12.33%
Apr-07-26 10:30AM	BC-Most Active Stocks (Associated Press) +86.29%
Mar-30-26 10:30AM	BC-Most Active Stocks (Associated Press) +15.64%
08:30AM	Loading…
08:30AM	Quince Therapeutics Settles Approximately $16.4 Million of Debt (Business Wire)
Feb-13-26 01:51AM	What Sparked Quince Therapeutics (QNCX) Stock To Rise 53% After Hours (Benzinga) -11.31%
Feb-12-26 12:27PM	Quince Therapeutics Stock Plunges As Filing Shows Reverse Merger Plans, Bankruptcy Risks (Benzinga) -63.03%
Feb-11-26 01:59PM	Quince Therapeutics Stock Extends Rally On Strategic Review (Benzinga) +15.60%
Feb-10-26 08:26PM	Quince Therapeutics, Spotify, S&P Global, Intel And Datadog: Why These 5 Stocks Are On Investors' Radars Today (Benzinga) +305.92%
03:05PM	Quince Therapeutics Stock Explodes 300% On Strategic Review (Benzinga)
05:58AM	Why Is Quince Therapeutics Stock Soaring Tuesday? (Benzinga)
Feb-09-26 04:05PM	Quince Therapeutics Engages LifeSci Capital as its Exclusive Financial Advisor to Explore Strategic Alternatives (Business Wire) -6.54%
Feb-02-26 07:19AM	Quince Therapeutics stock crashes on Phase III ataxia-telangiectasia failure (Clinical Trials Arena) +5.88%
Jan-30-26 09:54AM	Spotify upgraded, Pinterest downgraded: Wall Street's top analyst calls (The Fly) -37.06%
08:16AM	Loading…
08:16AM	Quince Therapeutics Stock Collapses After Key Trial Update In Rare Genetic Disease (Benzinga)
Jan-29-26 03:10PM	Quince Therapeutics Announces Topline Results from Pivotal Phase 3 NEAT Clinical Trial of eDSP in Ataxia-Telangiectasia (Business Wire) -91.51%
Jan-28-26 04:05PM	Quince Therapeutics Presents Safety Data from Long-Term eDSP Treatment in Children with Ataxia-Telangiectasia at British Paediatric Neurology Association Annual Meeting (Business Wire)
Dec-16-25 09:26AM	Quince Therapeutics price target raised to $5 from $4 at D. Boral Capital (TipRanks)
Dec-15-25 08:00AM	Quince Therapeutics Announces Last Patient Last Visit in Phase 3 NEAT Clinical Trial in Patients with Ataxia-Telangiectasia (Business Wire) -10.66%
Dec-10-25 04:05PM	Quince Therapeutics Announces Publication of Use of eDSP in Early-Stage Clinical Studies in Pulmonary and Inflammatory Bowel Disorders (Business Wire) +10.28%
Nov-24-25 08:00AM	Quince Therapeutics to Participate at Investor Events in December 2025 (Business Wire) +16.82%
Nov-12-25 04:05PM	Quince Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results (Business Wire)
Nov-10-25 04:05PM	Quince Therapeutics Announces Positive iDSMB Review for eDSP in Pivotal Phase 3 NEAT Clinical Trial in Ataxia-Telangiectasia (Business Wire) +11.87%
Oct-09-25 04:05PM	Quince Therapeutics Presents Data from Patient-Reported Walking Capacity in Children with Ataxia-Telangiectasia at 54th Child Neurology Society Annual Meeting (Business Wire) +6.25% -8.33%
Sep-25-25 04:05PM	Quince Therapeutics Announces CPT: Pharmacometrics & Systems Pharmacology Publication of eDSP Population Pharmacokinetic Modeling Study (Business Wire)
Sep-11-25 04:05PM	Quince Therapeutics to Host Virtual Investor Day on October 2, 2025 (Business Wire)
Sep-02-25 04:05PM	Quince Therapeutics to Present at H.C. Wainwright 27th Annual Global Investment Conference (Business Wire)
Aug-11-25 04:05PM	Quince Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results (Business Wire) +14.37%
Aug-07-25 08:00AM	Quince Therapeutics Selects Option Care Health as Specialty Infusion Therapy Provider for Administration of Lead Asset eDSP (Business Wire)
08:00AM	Loading…
Jul-16-25 08:00AM	Quince Therapeutics Completes Enrollment in Pivotal Phase 3 NEAT Clinical Trial in Ataxia-Telangiectasia (Business Wire)
Jul-10-25 04:05PM	Quince Therapeutics Appoints Leading Immunologist Dr. Hassan Abolhassani to Scientific Advisory Board (Business Wire)
Jun-25-25 04:05PM	Quince Therapeutics to Participate at A-T Societys 2025 A-T Clinical Research Conference (Business Wire) +10.34% -6.25%
Jun-18-25 04:05PM	Quince Therapeutics Announces Closing of Up to $22 Million Private Placement of Securities (Business Wire)
Jun-12-25 05:15PM	Quince Therapeutics Announces Pricing of Up to $22 Million Private Placement of Securities (Business Wire) +19.17%
Jun-03-25 04:05PM	Quince Therapeutics Exceeds 75% Enrollment in Pivotal Phase 3 NEAT Clinical Trial in Ataxia-Telangiectasia (Business Wire)
May-13-25 08:00AM	Quince Therapeutics Provides Business Update and Reports First Quarter 2025 Financial Results (Business Wire) -7.77%
May-04-25 06:46AM	Oppenheimer Predicts Up to ~840% Surge for These 2 Strong Buy Stocks (TipRanks)
Apr-30-25 04:05PM	Quince Therapeutics to Present at Citizens Life Sciences Conference (Business Wire)
Apr-03-25 04:05PM	Quince Therapeutics to Present at Jones Healthcare and Technology Innovation Conference (Business Wire)
Mar-24-25 04:05PM	Quince Therapeutics Provides Business Update and Reports Fiscal Year 2024 Financial Results (Business Wire)
Feb-07-25 08:00AM	Quince Therapeutics to Host Investor Webinar Today Focused on Addressing the High Unmet Need in Ataxia-Telangiectasia (Business Wire) -6.33%
Feb-05-25 04:05PM	Quince Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference (Business Wire) +7.74% -5.39%
Feb-04-25 04:05PM	Quince Therapeutics Receives Notice of Allowance Covering Innovative Method of Use for Lead Indication Ataxia-Telangiectasia (Business Wire)
Jan-28-25 08:00AM	Quince Therapeutics to Host Investor Webinar on February 7, 2025 Focused on Addressing the High Unmet Need in Ataxia-Telangiectasia (Business Wire) -6.98%
Jan-27-25 08:00AM	Quince Therapeutics Announces Frontiers in Neurology Publication of Long-Term Safety of EryDex in Pediatric Patients with Ataxia-Telangiectasia (Business Wire) +8.18%
Jan-23-25 04:05PM	Quince Therapeutics Appoints Renowned Pediatric Neurologist Dr. William Whitehouse to Scientific Advisory Board (Business Wire)
Nov-13-24 04:05PM	Quince Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results (Business Wire) -5.36% +19.50%
Nov-12-24 04:05PM	Quince Therapeutics Presents Data from Prior Phase 3 ATTeST Clinical Trial at 2024 International Congress for Ataxia Research (Business Wire)
Nov-11-24 04:05PM	Quince Therapeutics Presents Safety Data from Prior Phase 3 ATTeST Clinical Trial at 53rd Child Neurology Society Annual Meeting (Business Wire)
Oct-14-24 04:05PM	Quince Therapeutics to Participate at Upcoming Investor Conferences (Business Wire) +13.83%
Sep-03-24 04:05PM	Quince Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference (Business Wire)
Aug-16-24 04:12AM	Quince reports data from Phase III Ataxia-Telangiectasia treatment trial (Clinical Trials Arena)
Aug-15-24 07:00AM	Quince Therapeutics Announces The Lancet Neurology Publication of Phase 3 ATTeST Clinical Trial Data Evaluating EryDex for the Treatment of Ataxia-Telangiectasia (A-T) (Business Wire)
Aug-13-24 04:05PM	Quince Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results (Business Wire) -16.54%
Jun-26-24 07:13AM	Quince Therapeutics doses first subject in Ataxia-Telangiectasia trial (Clinical Trials Arena)
Jun-25-24 07:00AM	Quince Therapeutics Announces First Patient Dosed in Phase 3 Clinical Trial of EryDex for the Treatment of Ataxia-Telangiectasia (Business Wire)
Jun-04-24 07:15AM	FDA fast tracks Quince Therapeutics rare ataxia drug EryDex (Pharmaceutical Technology)
Jun-03-24 07:00AM	Quince Therapeutics Receives U.S. FDA Fast Track Designation for EryDex System (Business Wire) +5.66%
May-13-24 01:53PM	QNCX Stock Earnings: Quince Therapeutics Reported Results for Q1 2024 (InvestorPlace)
07:00AM	Quince Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results (Business Wire)
May-06-24 04:05PM	Quince Therapeutics to Present at The Citizens JMP Life Sciences Conference (Business Wire)
Apr-02-24 09:53AM	QNCX Stock Earnings: Quince Therapeutics Reported Results for Q4 2023 (InvestorPlace)
Apr-01-24 07:00AM	Quince Therapeutics Provides Business Update and Reports Fourth Quarter and Fiscal 2023 Financial Results (Business Wire)
Feb-22-24 07:00AM	Quince Therapeutics Launches Scientific Advisory Board (Business Wire)
Feb-15-24 07:00AM	Quince Therapeutics Appoints Former Reata Pharmaceuticals Chief R&D Officer Dr. Rajiv Patni to its Board of Directors (Business Wire)
Feb-07-24 04:05PM	Quince Therapeutics to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference (Business Wire)
Jan-04-24 04:05PM	Quince Therapeutics to Participate at Investor Events in January 2024 (Business Wire)
Dec-04-23 07:21AM	10 Best Debt Free Penny Stocks To Buy Now (Insider Monkey)
Oct-23-23 07:00AM	Quince Therapeutics Completes Acquisition of EryDel S.p.A. (Business Wire)
Sep-28-23 04:05PM	U.S. FDA Partial Clinical Hold Lifted on IND for EryDels Lead Phase 3 Asset EryDex for the Treatment of Ataxia-Telangiectasia (Business Wire)
Sep-06-23 07:00AM	Quince Therapeutics Appoints Dr. Charles S. Ryan as President (Business Wire)
Aug-15-23 10:20AM	Sidoti Events, LLCs Virtual August Micro-Cap Conference (ACCESSWIRE)
Aug-10-23 04:05PM	Quince Therapeutics to Present at Sidoti Virtual Investor Conference on August 17, 2023 (Business Wire)
Jul-24-23 07:00AM	Quince Therapeutics to Acquire EryDel SpA and its Phase 3 Asset Targeting Ataxia-Telangiectasia with No Currently Approved Treatments and Estimated $1+ Billion Peak Sales Opportunity (Business Wire) -27.22%
Jul-13-23 08:00AM	Echo Lake Capital Increase Offer to Acquire Quince Therapeutics, Inc. (ACCESSWIRE) +7.84%
Jun-06-23 08:00AM	Echo Lake Criticizes Quince Therapeutics Board for Enriching Themselves While Destroying Significant Shareholder Value (ACCESSWIRE)
Apr-11-23 07:00AM	Quince Therapeutics Board of Directors Unanimously Rejects Unsolicited Proposal from Echo Lake Capital (Business Wire)
Apr-06-23 04:05PM	Quince Therapeutics Engages MTS Health Partners as Independent Financial Advisor (Business Wire) -7.32%
Apr-05-23 04:05PM	Quince Therapeutics Adopts Limited Duration Stockholders Rights Plan (Business Wire) -6.70%
Mar-22-23 05:00AM	Quince Therapeutics Confirms Receipt of Unsolicited Acquisition Offer from Echo Lake Capital (Business Wire)
Mar-21-23 08:00AM	Echo Lake Capital Offers to Acquire Quince Therapeutics, Inc. (ACCESSWIRE) +71.10%
Jan-30-23 04:05PM	Quince Therapeutics Provides Pipeline Update and Business Outlook for 2023 (Business Wire) -7.41%
Jan-27-23 08:00AM	Quince Therapeutics Completes the Sale of Legacy Protease Inhibitor Portfolio to Lighthouse Pharmaceuticals (Business Wire) +33.66%
Nov-21-22 09:09AM	We Think Quince Therapeutics (NASDAQ:QNCX) Needs To Drive Business Growth Carefully (Simply Wall St.)
Sep-16-22 08:00AM	Quince Therapeutics Presents Preclinical Data at MHSRS 2022 Demonstrating Preclinical Efficacy of Bone-targeting Platform for Traumatic Bone Injury (Business Wire) -6.83%
Sep-12-22 08:00AM	Quince Therapeutics Presents Preclinical Data at ASBMR 2022 Demonstrating Application of Bone-targeting Platform for Spinal Fusion and Bone Cancer Indications (Business Wire)
Aug-30-22 04:05PM	Quince Therapeutics Presents Preclinical Data at OI 2022 Demonstrating Potential of a Targeted Anabolic for Accelerated Bone Healing of Osteogenesis Imperfecta Fractures (Business Wire)
Aug-25-22 04:05PM	Quince Therapeutics to Present at Upcoming Scientific Meetings (Business Wire)
Aug-04-22 08:00AM	Quince Therapeutics to Present at Canaccord Genuity 42nd Annual Growth Conference on August 11, 2022 (Business Wire)
Aug-01-22 08:00AM	Quince Therapeutics Details Strategic Growth Plan with Launch of New Corporate Name (Business Wire)

Quince Therapeutics, Inc. is a biopharmaceutical company, which engages in the unlocking the power of a patient's biology for the treatment of rare diseases. Its product includes EryDex, developed using their proprietary Autologous Intracellular Drug Encapsulation (AIDE) technology platform, which is a novel device combination that uses an automated process designed to encapsulate a drug into the patient's own red blood cells. The company was founded by Casey Crawford Lynch, Stephen Dominy, and Kristen Gafric on June 20, 2012 and is headquartered in South San Francisco, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
LUCA BENATTI	OFFICER	Dec 26 '25	Proposed Sale	3.46	50,000	173,211		Dec 29 05:51 PM
Benatti Luca	Director	Dec 26 '25	Sale	3.47	50,000	173,500	39,179	Dec 29 05:36 PM
Hannah Brendan	CBO, COO & CCO	Dec 05 '25	Option Exercise	0.91	27,551	25,012	361,827	Dec 08 08:12 AM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

QNCX

Quince Therapeutics Inc

Upgrade your Finviz experience